Castle Biosciences (CSTL) Change in Account Payables (2018 - 2026)

Castle Biosciences has disclosed Change in Account Payables across 9 years of filings, most recently posting $3.2 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $3.2 million, up 419.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (up 269.6% YoY), and the FY2025 annual result was $3.1 million, up 170.4% from the prior year.
• Change in Account Payables came in at $3.2 million for Q1 2026 at Castle Biosciences, up from -$17000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.9 million in Q1 2023 to a low of -$2.2 million in Q3 2024.
• The 5-year median for Change in Account Payables is $115000.0 (2022), against an average of $481647.1.
• Peak annual rise in Change in Account Payables reached 1983.42% in 2023, while the deepest fall reached 817.39% in 2023.
• Castle Biosciences' Change in Account Payables stood at -$1.6 million in 2022, then surged by 291.61% to $3.0 million in 2023, then plunged by 118.91% to -$570000.0 in 2024, then jumped by 97.02% to -$17000.0 in 2025, then surged by 18882.35% to $3.2 million in 2026.
• The last three Change in Account Payables figures came in at $3.2 million (Q1 2026), -$17000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.